Skip to main content

Qualified laboratory research use only. Not for human or veterinary use, consumption, administration, compounding, diagnosis, or treatment.

RESEARCH USE ONLY

Technical research brief

Selank: Identity, Evidence, and Documentation

A source-backed research brief covering Selank identity, model-system evidence, interpretation limits, and lot documentation.

4 min readMechanistic and animal-model evidencePrimary sources linked

Selank is cataloged here as a synthetic tuftsin-derived heptapeptide. Selank is a seven-amino-acid peptide derived from the tuftsin sequence. Published mechanistic work has examined GABA-receptor binding and neurotransmission-related gene expression, mostly in laboratory and animal systems.

Scope of this brief

This page separates molecular identity, published model-system observations, and procurement documentation. It is not a protocol and contains no instructions for administration or personal use.

Identity before interpretation

The literature may refer to Selank free base, acetate, or other characterized preparations. Counter-ion and lot identity should be kept explicit in any research record.

A short catalog name is a starting point, not a complete material characterization. Reproducible work begins by matching the named material to its sequence or chemical form, SKU, lot, nominal quantity, analytical method, and the actual result reported for that sample.

Research questions in the literature

  • GABA-receptor binding and proposed allosteric modulation in membrane preparations.
  • Short-term neurotransmission-related gene-expression changes in rat frontal cortex.
  • How molecular form, model system, and regional literature affect interpretation.

These topics describe what investigators measured. They should not be converted into treatment language, consumer promises, or an assumption that a finding transfers across species, tissues, preparations, or experimental conditions.

Evidence map

  • A 2016 rat study measured time-dependent expression changes in a panel of neurotransmission-related genes after Selank or GABA exposure.
  • A 2018 receptor-binding study described concentration-dependent modulation of radiolabeled GABA binding.
  • Mechanistic similarity does not establish equivalence to a medicine, a clinical outcome, or safety for personal use.

Evidence strength depends on the question. A receptor assay can inform target engagement; a cell model can inform a pathway hypothesis; an animal model can inform a defined biological system. None of those alone proves clinical safety, effectiveness, or suitability of a separately sourced material.

Interpretation guardrails

  • Much of the accessible literature is mechanistic, animal-based, or regionally published; broad clinical conclusions are not warranted.
  • FDA identifies limited safety information and immunogenicity and peptide-impurity concerns for compounded drugs containing Selank acetate.
  • This catalog material is not a drug, supplement, or product for administration.

Vespera does not translate this literature into dosing, reconstitution, injection, route-of-use, diagnosis, treatment, or veterinary guidance. If a project requires those claims, this catalog and this brief are not the appropriate source.

Lot and COA review

  • Record sequence, counter-ion or salt form, SKU, lot, nominal quantity, and analytical method.
  • Treat gene-expression and receptor-binding results as model-specific measurements.
  • Keep identity, purity, quantity, endotoxin, and sterility questions analytically separate.

Chromatographic purity, mass confirmation, quantity, endotoxin, microbial controls, residual solvents, water content, and stability answer different questions. A single headline percentage should not be used as a universal quality score.

Primary and official sources

Read the methods, model, material description, limitations, and conflicts of interest in the source itself.

  1. Volkova et al. — Selank and neurotransmission-related gene expression (2016)Rat frontal-cortex gene-expression study.
  2. Vyunova et al. — Selank and GABA-receptor binding (2018)Radioligand receptor study.
  3. FDA — bulk substances that may present significant safety risksRegulatory context for compounded drugs containing Selank acetate.
Research-use boundary

This educational summary does not make the Vespera catalog item a drug, medicine, supplement, cosmetic, compounded preparation, or consumer product. It is not for human or veterinary use.